|
1
|
Greaves WO, Verma S, Patel KP, Davies MA,
Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ
and Luthra R: Frequency and spectrum of BRAF mutations in a
retrospective, single-institution study of 1112 cases of melanoma.
J Mol Diagn. 15:220–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wan PT, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D and Marais R; Cancer Genome Project, : Mechanism of
activation of the RAF-ERK signaling pathway by oncogenic mutations
of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beck D, Niessner H, Smalley KS, Flaherty
K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen
S, et al: Vemurafenib potently induces endoplasmic reticulum
stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal.
6:ra72013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Long GV, Menzies AM, Nagrial AM, Haydu LE,
Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA and
Kefford RF: Prognostic and clinicopathologic associations of
oncogenic BRAF in metastatic melanoma. J Clin Oncol. 29:1239–1246.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heinzerling L, Kühnapfel S, Meckbach D,
Baiter M, Kaempgen E, Keikavoussi P, Schuler G, Agaimy A, Bauer J,
Hartmann A, et al: Rare BRAF mutations in melanoma patients:
Implications for molecular testing in clinical practice. Br J
Cancer. 108:2164–2171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dhillon AS and Kolch W: Oncogenic B-Raf
mutations: Crystal clear at last. Cancer Cell. 5:303–304. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jones DT, Kocialkowski S, Liu L, Pearson
DM, Ichimura K and Collins VP: Oncogenic RAF1 rearrangement and a
novel BRAF mutation as alternatives to KIAA1549: BRAF fusion in
activating the MAPK pathway in pilocytic astrocytoma. Oncogene.
28:2119–2123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moretti S, Macchiarulo A, De Falco V,
Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L,
Santeusanio F, et al: Biochemical and molecular characterization of
the novel BRAF(V599Ins) mutation detected in a classic papillary
thyroid carcinoma. Oncogene. 25:4235–4240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schulten HJ, Salama S, Al-Mansouri Z,
Alotibi R, Al-Ghamdi K, Al-Hamour OA, Sayadi H, Al-Aradati H,
Al-Johari A, Huwait E, et al: BRAF mutations in thyroid tumors from
an ethnically diverse group. Hered Cancer Clin Pract. 10:102012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gauchotte G, Philippe C, Lacomme S,
Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM
and Bressenot A: BRAF, p53 and SOX2 in anaplastic thyroid
carcinoma: Evidence for multistep carcinogenesis. Pathology.
43:447–452. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barollo S, Pezzani R, Cristiani A,
Redaelli M, Zambonin L, Rubin B, Bertazza L, Zane M,
Mucignat-Caretta C, Bulfone A, et al: Prevalence, tumorigenic role,
and biochemical implications of rare BRAF alterations. Thyroid.
24:809–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhardt AE, Olbrich H, Röring M,
Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister
SM, et al: Functional characterization of a BRAF insertion mutant
associated with pilocytic astrocytoma. Int J Cancer. 129:2297–2303.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu J, Deshmukh H, Gutmann RJ, Emnett RJ,
Rodriguez FJ, Watson MA, Nagarajan R and Gutmann DH: Alterations of
BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.
Neurology. 73:1526–1531. 2009. View Article : Google Scholar : PubMed/NCBI
|
